Market closedNon-fractional

BioAtla/BCAB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About BioAtla

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Ticker

BCAB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Diego, United States

Employees

65

BioAtla Metrics

BasicAdvanced
$64M
Market cap
-
P/E ratio
-$2.49
EPS
1.21
Beta
-
Dividend rate
$64M
1.21
4.487
4.186
0.835
3.87
-53.28%
-115.68%
1.28
1.28
-0.563
-5.85%
23.97%

What the Analysts think about BioAtla

Analyst Ratings

Majority rating from 5 analysts.
Buy

BioAtla Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$23M
-13.75%
Profit margin
0.00%
NaN%

BioAtla Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.44%
QuarterlyAnnual
Q2 23
Q3 23
Q1 24
Q2 24
Actual
-$0.75
-$0.70
-$0.48
-
Expected
-$0.64
-$0.80
-$0.54
-$0.44
Surprise
17.19%
-12.50%
-11.44%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for BioAtla stock?

BioAtla (BCAB) has a market cap of $64M as of July 06, 2024.

What is the P/E ratio for BioAtla stock?

The price to earnings (P/E) ratio for BioAtla (BCAB) stock is 0 as of July 06, 2024.

Does BioAtla stock pay dividends?

No, BioAtla (BCAB) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next BioAtla dividend payment date?

BioAtla (BCAB) stock does not pay dividends to its shareholders.

What is the beta indicator for BioAtla?

BioAtla (BCAB) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell BioAtla stock

Buy or sell BioAtla stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing